We retrospectively identified 14 elderly patients with a history of partial seizures who received levetiracetam (LEV) monotherapy. Patients began LEV either as first line therapy (n = 5) or were converted to LEV monotherapy (n = 9) after failing prior antiepileptic medications (AEDs). Thirteen patients continued on LEV monotherapy for at least 6 months. One patient was lost to follow-up. Eight patients (61.5%) became seizure free. Four patients who began LEV as a first line therapy became seizure free, whereas the remaining four patients who converted to LEV after they failed their previous AEDs became seizure free. Four patients (30.7%) had more than a 50% seizure reduction of seizures. Only one patient had no significant change in seizure frequency after started on LEV. The total dosages used to control seizures were 500-3000 mg/day, (mean 1839.2 mg/day). LEV monotherapy can be effective and well tolerated in this group of patients. A prospective, larger, double blind monotherapy study is needed to confirm this finding.
INTRODUCTION
Advanced age patients ≥60 years of age may have an increased sensitivity to the effects of AEDs, due to age-dependent changes in pharmacokinetics and pharmacodynamics. Pharmacokinetic changes may include a lower degree of drug binding to plasma proteins and decreased metabolic and renal drug clearance 1 .
Levetiracetam (LEV) has been approved as adjunctive treatment for adults with partial onset seizures 2, 3 . LEV has a favorable pharmacokinetic profile that includes minimal protein binding, lack of hepatic metabolism, and twice a day dosing 4 . These features and others make it ideal for use as monotherapy in elderly patients. We wished to evaluate our experience with LEV as monotherapy in this group of patients to examine its efficacy and tolerability.
METHODS
We retrospectively reviewed the charts of all of our elderly patients aged 60 and above with a confirmed diagnosis of epilepsy who had two unprovoked seizures. Forty-five patients were identified. Of these, 14 patients were tried on LEV either as first line therapy or were converted to LEV monotherapy after failing their prior antiepileptic medications (AEDs).
We reviewed demographic data, diagnostic evaluation for epilepsy, seizure types, and seizure frequency prior to and following initiation of LEV monotherapy. All patients had their LEV dose titrated up to 3000 mg/day or up to seizure freedom. We compared baseline seizure counts from 3 months prior to initiation of LEV treatment to seizure counts at 6 months of follow-up after LEV was started and maintained as therapy. Seizure frequency was determined using a seizure diary completed by each patient or their caregivers, which is standard practice in our clinic. Adverse events (AEs) while on LEV were also noted at each clinic visit. This information was kept in a computerised data system that was maintained up-to-date.
RESULTS
We identified 14 patients, ages 62-92 years, mean (66 years) with a history of partial seizures with and without secondarily generalisation. The duration of epilepsy ranged from 1 to 39 years (mean 12.6 years, median 2.5). Eight patients were diagnosed with epilepsy after the age of 60. Five patients began LEV as first line therapy. Two of these patients had liver disease and consequently wished to avoid AEDs that required hepatic metabolism. The remaining three patients chose to start LEV because of its favorable pharmacokinetic and side-effect profile. Nine patients were converted to LEV monotherapy after they failed their initial trials of AEDs, which included Dilantin, Tegretol, Depakote, and Lamictal (mean 1.6).
Of the eight newly diagnosed patients, two had AD and one patient had stroke as a cause of epilepsy. The remaining six chronic patients had an identifiable cause to their seizures: two secondary to head trauma, two secondary to strokes, and two secondary to Alzheimer disease (AD).
Of the 14 patients, 13 (93%) of the patients continued on LEV monotherapy for at least 6 months. One patient was lost to follow-up. Eight patients (61.5%) became seizure free. Four patients who began LEV as monotherapy became seizure free, whereas the remaining four patients who began LEV as add-on therapy and remained on LEV as monotherapy became seizure free.
Two patients (15%) had more than a 50% but less than 75% seizure reduction and two patients (15%) had more than a 75% but less than 100% reduction of seizures. One patient with newly diagnosed epilepsy (less than 2 years duration) had no significant change in her seizure frequency. The total dosages used to control seizures for all patients were 500-3000 mg/day (mean 1839.2 mg/day). Characteristics and demographics of our group of patients are summarised in Table 1 .
One patient reported being dizzy within days after starting LEV but was able to continue on LEV. All patients were required to have liver function tests, complete blood counts at baseline prior to start LEV, and at 6 months follow-up. No blood abnormalities were noted and no other major AEs were reported. 
DISCUSSION
This study suggests that LEV monotherapy can be effective in newly diagnosed elderly epilepsy patients ≥60 years of age who were AED-naive, as well as in elderly patients with chronic epilepsy. Of the eight patients with newly diagnosed epilepsy, six patients became seizure free after at least 6 months of follow-up, while one patient had no significant change in seizure frequency, and one patient was lost to follow-up. These findings support the current belief that most older patients will remain seizure free on AED monotherapy 5 . Inadequate seizure control in this group could suggest poor compliance or progressive disease. Information on efficacy and tolerability of established, as well as new AEDs, is scarce in the elderly population. Few randomised controlled trials have been undertaken in this age group utilising old and new AEDs 6, 7 . Previous work utilising LEV as an add-on therapy for 78 patients ≥65 years of age have shown complete seizure reduction in 40% of patients, while 76% achieved more than a 50% reduction of seizures 8 . In that study, more than half of the patients were taking 1000 mg/day. To our knowledge, this current report is the first one studying the efficacy and tolerability of LEV as monotherapy in this patient population. Previous work at this center, as well as the work of others have demonstrated that LEV can be effective as monotherapy in newly diagnosed adult patients as well as in patients with difficult to control seizures 9, 10 .
It has been noted that the elderly have generally increased sensitivity to medications; a factor that may account for the increased incidence of poor tolerability and poor compliance. Several factors can influence the pharmacokinetics and pharmacodynamics of AEDs in the elderly. Of particular concern is the lowered serum albumin that frequently occurs in older patients. In addition, many of these patients take other medication for various medical conditions that require prolonged treatment. It is estimated that the average number of medication among older ambulatory people screened for undetected medical illnesses is 3.7 medications per patient 11 . Of the new AEDs, LEV is believed to be free of drug-drug interactions and minimally protein bound. This suggests that LEV may be an ideal choice for this elderly group of patients.
The small number of patients studied, as well as the retrospective nature of this study and the short-term follow-up, along with lack of randomisation may not allow us to make firm conclusions. However, our preliminary data suggests that LEV may be an acceptable choice as monotherapy for the elderly. It is very well tolerated, with minimum reports of minor side effects. A prospective, large, double blind study is needed to confirm this finding.
